Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 8553311.
- Also identified by PMC identifier 1021361.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 28 year old man with asthma, bronchopulmonary aspergillosis, pulmonary thromboembolic disease, and pulmonary hypertension developed Aspergillus fumigatus empyema complicating a pneumothorax. His condition progressively deteriorated despite treatment with intravenous and intrapleural amphotericin B, but improved promptly after substituting nebulised liposomal amphotericin B and oral itraconazole. This experience suggests that nebulised liposomal amphotericin B is well tolerated and merits further assessment in the treatment of pulmonary fungal disease.
Medical subject headings
- Amphotericin B
- Antifungal Agents
- Aspergillosis
- Aspergillus fumigatus
- Empyema, Pleural